Current state of cardiac amyloidosis

Current Opinion in Cardiology

Volumn 28, Issue 2, 2013, Pages 242-248

  Sharma, Nakul ^a   Howlett, Jonathan ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

amyloidosis; cardiac amyloid; diagnosis; heart failure; treatment

Indexed keywords

AMYLOID; AMYLOID PROTEIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BORTEZOMIB; CALCIUM CHANNEL BLOCKING AGENT; CONGO RED; MELPHALAN; MIDODRINE; SERUM AMYLOID; SERUM AMYLOID A; TECHNETIUM 99M; UNCLASSIFIED DRUG; WARFARIN;

AUTONOMIC DYSFUNCTION; CARDIAC PATIENT; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL EXAMINATION; CLINICAL FEATURE; COMPRESSION STOCKING; DEVICE THERAPY; DISEASE COURSE; DRUG MEGADOSE; DRUG TOLERABILITY; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FAMILY HISTORY; GOLD STANDARD; HEART AMYLO; HEART AMYLOIDOSIS; HEART ATRIUM ENLARGEMENT; HEART ATRIUM FIBRILLATION; HEART CATHETERIZATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPOTENSION; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; ISOLATED ATRIAL AMYLOIDOSIS; LIFE EXPECTANCY; LIGHT CHAIN; LONG TERM SURVIVAL; MULTIPLE MYELOMA; PATHOPHYSIOLOGY; PRIMARY AMYLOIDOSIS; PRIORITY JOURNAL; REVIEW; SENILE SYSTEMIC AMYLOIDOSIS; SODIUM RESTRICTION; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

AMYLOIDOSIS; BIOLOGICAL MARKERS; CARDIAC CATHETERIZATION; ELECTROCARDIOGRAPHY; HEART DISEASES; HEART TRANSPLANTATION; HUMANS; MAGNETIC RESONANCE IMAGING; PACEMAKER, ARTIFICIAL; PROGNOSIS;

EID: 84873476283     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32835dd165     Document Type: Review

References (51)

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349:583-596.
2. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997; 337:898-909.
3. Gertz MA, Lacy MQ, Dispenzieri A. Amyloidosis. Hematol Oncol Clin North Am 1999; 13:1211-1233.
4. Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989.
5. Gutierrez PS, Fernandes F, Mady C, Higuchi Mde L. Clinical, electrocardiographic and echocardiographic findings in significant cardiac amyloidosis detected only at necropsy: comparison with cases diagnosed in life. Arq Bras Cardiol 2008; 90:191-196.
6. Westermark W Benson M.D. Buxbaum J.N. et al A primer of amyloid nomenlr. Amyloid 2007; 14:179-183.
7. Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid 2010; 17:101-104.
8. Kisilevsky R. The relation of proteoglycans, serum amyloid P and apo E to amyloidosis current status, 2000. Amyloid 2000; 7:L23-L25.
9. Vanden Driesen R, Slaughter R, Strugnell W. MR findings in cardiac amyloidosis. Am J Roentgenol 2006; 186:1682-1685.
10. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005; 112:2047-2060.
11. Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light chain (AL) amyloidosis with heart involvement. QJM 1998; 91:141-157.
12. Chaamarthi B, Dubrey SW, Cha K, et al. Features and prognosis of exertional syncope in light-chain associated AL cardiac amyloidosis. Am J Med 2000; 109:181-188.
13. Tyberg TI, Goodyer AV, Hurst VWD, et al. Left ventricular filling in differentiating restrictive amyloid cardiomyopathy and constrictive pericarditis. Am J Cardiol 1981; 47:791-796.
14. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32:45-49.
15. Dubrey SW, Cha K, Simms RW, et al. Electrocardiography and Doppler echocardiography in secondary (AA) amyloidosis. Am J Cardiol 1996; 77:313-315.
16. Saraiva MJ. Sporadic cases of hereditary systemic amyloidosis. N Engl J Med 2002; 346:1818-1819.
17. Cornwell GG, Murdoch WL, Kyle RA, et al. Frequency and distribution of senile cardiovascular amyloid: A clinicopathologic correlation. Am J Med 1983; 75:618-623.
18. Ng B, Connors LH, Davidoff R, et al. Senile systemic amyloidosis presenting with heart failure: A comparison with lightchain-associated amyloidosis. Arch Intern Med 2005; 165:1425-1429.
19. Leone O, Boriani G, Chiappini B, et al. Amyloid deposition as a cause of atrial remodeling in persistent valvular atrial fibrillation. Eur Heart J 2004; 25:1237-1241.
20. Westermark P, Johansson B, Natvig JB. Senile cardiac amyloidosis: Evidence of two different amyloid substances in the ageing heart. Scand J Immunol 1979; 10:303-308.
21. Cheng ZW, Tian Z, Kang L, et al. Electrocardiographic and echocardiographic features of patients with primary cardiac amyloidosis [in Chinese]. Zhonghua Xin Guan Bing Zhi 2010; 38:606-609.
22. Murtagh B, Hammill SC, Gertz MA, et al. Electrocardiographic findings in primary systemic amyloidosis and biopsy proven cardiac involvement. Am J Cardiol 2005; 95:535-537.
23. Kristen AV, Perz JB, Schonland SO, et al. Rapid progression of left ventricular wall thickness predicts mortality in cardiac light-chain amyloidosis. J Heart Lung Transplant 2007; 26:1313-1319.
24. Feng D, Syed IS, Martinez M, et al. Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation 2009; 118:2490-2497.
25. Patel AR, Dubrey SW, Mendes LA, et al. Right ventricular dilation in primary amyloidosis: An independent predictor of survival. Am J Cardiol 1997; 80:488-492.
26. Koyama J, Ray-Sequin PA, Davidoff R, et al. Usefulness of pulsed tissue Doppler imaging for evaluating systolic and diastolic left ventricular function in patients with AL (primary) amyloidosis. Am J Cardiol 2002; 89:1067-1071.
27. Koyama J, Davidoff R, Falk RH. Longitudinal myocardial velocity gradient derived from pulsed Doppler tissue imaging in AL amyloidosis: A sensitive indicator of systolic and diastolic dysfunction. J Am Soc Echocardiogr 2004; 17:36-44.
28. Swanston RH, Brooksby IA, Davies MJ, et al. Systolic and diastolic ventricular function in cardiac amyloidosis: Study of six cases diagnosed with endomyocardial biopsy. Am J Cardiol 1977; 39:658-664.
29. Lorell BH, Grossman W. Profiles in constrictive pericarditis, restrictive cardiomyopathy and cardiac tamponade. Grossman's Cardiac catheterization, angiography and intervention. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006. pp. 829-850.
30. Pomerance A, Slavin G, McWatt J. Experience with the sodium sulphate-Alcian blue stain for amyloid in cardiac pathology. J Clin Pathol 1976; 29: 22-26.
31. Ardehali H, Qasim A, Cappola T, et al. Endomyocardial biopsy plays a role in diagnosing patients with unexplained cardiomyopathy. Am Heart J 2004; 147:919-923.
32. Ansari-Lari MA, Ali SZ. Fine needle aspiration of abdominal fat pad for amyloid detection: A clinically useful test? Diagn Cytopathol 2004; 30: 178-181.
33. Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999; 100:1992-2002.
34. Mahrholdt H, Wagner A, Judd RM, et al. Delayed enhancement cardiovascular magnetic resonance assessment of nonischemic cardiomyopathies. Eur Heart J 2005; 26:1461-1474.
35. Austin BA, Tang WH, Rodriguez ER, et al. Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging 2009; 2:1369-1377.
36. Syed IS, Glockner JF, Feng D, et al. Role of cardiac magnetic resonance imaging in detection of cardiac amyloidosis. JACC Cardiovasc Imaging 2010; 3:155-164.
37. Di Bella G, Minutoli F, Mazzeo A, et al. MRI of cardiac involvement in transthyretin familial amyloid polyneuropathy. Am J Roentgenol 2010; 195:W394-W399.
38. Hawkins PN. Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. Curr Opin Nephrol Hypertens 2002; 11:649-655.
39. Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono1,2- propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005; 46:1076-1084.
40. Nordlinger M, Magnani B, Skinnet M, et al. Is elevated plasma B-natriuretic peptide in amyloidosis simply a function of the presence of heart failure? Am J Cardiol 2005; 96:982-984.
41. Dispenzieri A, Kyle RA, Gertz MA, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003; 361:1787-1789.
42. Berk JL, Keane J, Seldin DC, et al. Persistent pleural effusions in primary systemic amyloidosis: Etiology and prognosis. Chest 2003; 124:969-977.
43. Shah KB, Inoue Y, Mehra MR. Amyloidosis and the heart: A comprehensive review. Arch Intern Med 2006; 166:1805-1813.
44. Rubinow A, Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation 1981; 63:1285-1288.
45. Gertz MA, Falk RH, Skinner M, et al. Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. Am J Cardiol 1985; 55:1645.
46. Skinner M, Sanchorawala V, Seldin DC, et al. High dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8 year study. Ann Intern Med 2004; 140:85-93.
47. Dubrey SW, Burke MM, Hawkins PN, et al. Cardiac transplantation for amyloid heart disease: The United Kingdom experience. J Heart Lung Transplant 2004; 23:1142-1153.
48. Bonvini P, Zorzi E, Basso G, Rosolen A. Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30 anaplastic large cell lymphoma. Leukemia 2007; 21:838-842.
49. Wright BL, Grace AA, Goodman HJ. Implantation of cardioverter defibrillator in a patient with cardiac amyloidosis. Nat Clin Pract Cardiovasc Med 2006; 3:110-114.
50. Gillmore JD, Goodman HJ, Lachmann HJ, et al. Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood 2006; 107:1227-1229.
51. Adams J, Kauffman M. Development of the proteasome inhibitor velcade (Bortezomib). Cancer Invest 2004; 22:304-311.